Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
skin infections
Biotech
Histogen halts last remaining programs to conserve cash
Could Histogen soon join the growing list of biotechs shutting up shop for good in 2023?
James Waldron
Jul 6, 2023 9:00am
Nabriva halts R&D, lays off 40% of staff in commercial refocus
Nov 11, 2022 7:35am
After cancer flops, Celldex shows promise in treating hives
Jul 12, 2021 8:05am
AnaptysBio's dermatology drug misses the mark in phase 2
Mar 8, 2021 9:35am
Lilly bags late-phase Dupixent rival in $1.1B Dermira buyout
Jan 10, 2020 8:20am
Leo's Dupixent rival hits all endpoints in pivotal program
Dec 11, 2019 7:20am
